Bruker (BRKR +4.31%) published its latest quarterly earnings report Monday morning, and despite notching a double beat the company's stock took something of a hit. Its price fell nearly 1% by the closing bell, as investors didn't take kindly to a double miss on full-year guidance. Earlier in the trading session, Bruker dipped as much as 3.9%.
Strength in niche segments
Bruker, which specializes in the supply of medical devices and scientific instruments, earned revenue of almost $861 million in its third quarter. This number was down 0.5% from the same period of 2024.
Image source: Getty Images.
The company's bottom line according to generally accepted accounting principles (GAAP) flipped to a net loss of $62 million, against the nearly $41 million profit in the year-ago quarter. Things looked better on a non-GAAP (adjusted) basis, as Bruker was profitable to the tune of $0.45 per share against third quarter 2024's $0.60 net income.
On average, analysts tracking the company's stock were anticipating revenue of $847 million, and per-share, adjusted net income of $0.33.
Bruker said that it benefited from bookings in the academic and government customer segments during the quarter, in addition to strength in the biotech sector.
NASDAQ: BRKR
Key Data Points
Chop, chop
As any seasoned investor knows, however, stocks typically trade on future potential rather than trailing wins.
Bruker lowered its full-year 2025 guidance, and this dimmed the good parts of its earnings release. The company is now forecasting it will book revenue of $3.41 billion to $3.44 billion this year. By comparison, 2024's top line was $3.37.
As for adjusted net income, that guidance has been trimmed to $1.85 to $1.90 per share. That's well down from the 2024 result of $2.41.
